Streetbeat News

CELZ

Creative Medical Technology Holdings, Inc.

https://www.creativemedicaltechnology.com

Industry

Biotechnology

Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Open

2.70

Mkt cap

4.4M

Volume

51K

High

2.82

P/E Ratio

-0.66

52-wk high

10.28

Low

2.48

Div yield

N/A

52-wk low

2.48

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) announced a positive independent safety review for its ADAPT clinical trial, validating the safety and potential of CELZ-201 for treating chronic lower back pain.

Portfolio Pulse from

November 13, 2024 | 2:15 pm

Creative Medical Technology shares declined following the announcement of a $1.85 million registered direct offering priced at the market under Nasdaq rules.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 1:25 pm

In Wednesday's pre-market session, several healthcare stocks experienced significant price movements. CNS Pharma, DBV Technologies, and Cyclacel Pharmaceuticals were among the top gainers, while Alto Neuroscience and Ensysce Biosciences saw notable declines.

Portfolio Pulse from Benzinga Insights

October 23, 2024 | 12:08 pm

In Wednesday's pre-market session, several healthcare stocks experienced significant price movements. CNS Pharma, DBV Technologies, and Cyclacel Pharmaceuticals saw substantial gains, while Alto Neuroscience and Ensysce Biosciences faced notable declines.

Portfolio Pulse from Benzinga Insights

October 23, 2024 | 12:07 pm

Creative Medical Technology Holdings has announced a $1.85 million registered direct offering, pricing 418,552 shares at $4.42 each, under Nasdaq rules.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 12:06 pm

Creative Medical Technology Holdings (CELZ) has developed an AI-driven diagnostic and treatment program for biologic and chemical exposure.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 1:02 pm

Creative Medical Technology has successfully generated human induced pluripotent stem cells (iPSC)-derived islet cells that produce human insulin.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 12:35 pm

In Thursday's after-market session, health care stocks showed significant movement. Ainos (AIMD) led the gainers with a 100% increase, while Biofrontera (BFRI) experienced the largest decline at 15.1%. Other notable movers include Talphera (TLPH) and Macrogenics (MGNX), with their recent Q4 earnings influencing their stock prices.

Portfolio Pulse from Benzinga Insights

March 07, 2024 | 9:31 pm

HighPeak Energy, Inc. (NASDAQ:HPK) shares fell by 15.3% after reporting lower-than-expected Q4 revenue, despite beating EPS estimates. Other stocks showed significant movement, with Lytus Technologies Holdings PTV. Ltd. (NASDAQ:LYT) leading gainers with a 404% jump after announcing the launch of Lytus Cloud. On the losing end, Solowin Holdings (NASDAQ:SWIN) dropped 31.6% after a previous day's surge. The market saw a mix of dramatic gains and losses across various sectors.

Portfolio Pulse from Avi Kapoor

March 07, 2024 | 6:35 pm

Creative Medical Technology Holdings Inc (NASDAQ:CELZ) saw its stock surge after receiving FDA authorization for CELZ-201, a therapy aimed at managing abnormal glucose tolerance and preventing Type 1 diabetes in high-risk individuals. This groundbreaking therapy represents a significant advancement in personalized medicine for diabetes management. Additionally, CELZ received Orphan Drug Designation for CELZ-101, ImmCelz, to prevent allograft rejection in pancreatic islet cell transplantation for Type 1 diabetes patients. CELZ shares rose 34.50% to $6.40.

Portfolio Pulse from Vandana Singh

March 07, 2024 | 6:16 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.